Get started
Author

Linda Gojenola

Observed name: L. Gojenola
OpenAlex ID: A5067766370
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
2020 · Everett J. Moding, Yufei Liu, et al. · Nature Cancer · 366
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
2020 · Barzin Y. Nabet, Mohammad S. Esfahani, et al. · Cell · 347
PDF
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
2016 · David A. Hinds, Kimberly E. Barnholt, et al. · Blood · 268
PDF
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2020 · Michael S. Binkley, Young-Jun Jeon, et al. · Cancer Discovery · 164
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2020 · Matthew D. Hellmann, Barzin Y. Nabet, et al. · Clinical Cancer Research · 125
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells
2019 · Johan Jeong, Astraea Jager, et al. · Blood Advances · 33
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia
2017 · Alfred Chung, Yanli Hou, et al. · Cancer Genetics · 20
Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes
2013 · J. D. Merker, K. M. Roskin, et al. · Haematologica · 12
PDF
Development and clinical validation of a targeted RNAseq panel (Fusion-STAMP) for diagnostic and predictive gene fusion detection in solid tumors
2019 · Erik Nohr, Christian A. Kunder, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al. · 1
Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice
2019 · Pedro G Vianna, Richard D. Press, et al. · Blood · 1
Feasibility of using microbeads with holographic barcodes to track DNA specimens in the clinical molecular laboratory
2013 · Jason D. Merker, Naomi O’Grady, et al. · PeerJ · 1
Data from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Tables S1-S7 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Figures 1-9 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Tables S1-S7 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Figures 1-9 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
PDF
Data from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Table S1 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Tables S2-S7 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
PDF
Table S1 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
PDF
Supplementary Tables S2-S7 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Works count: 30
Citation count: 1,344
H-index: 8
I10-index: 8
Year
Topic
Type